Curcumin Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease: Mechanism Exploration, Clinical Application Strategies, and Application Limitations Challenges

Metabolic dysfunction-associated steatotic liver disease (MASLD), as a liver phenotype of metabolic syndrome, has a global prevalence of up to 32.4%. Its pathogenesis involves complex pathological networks, including lipid metabolism disorders, oxidative stress, inflammation, and insulin resistance. Faced with the limitations of existing single-target drugs, curcumin, a natural polyphenolic compound, has demonstrated significant potential for the prevention and treatment of MASLD due to its multidimensional pharmacological activities, such as antioxidant, anti-inflammatory, metabolic regulation, and mitochondrial function repair. This article provides a systematic review of recent research on curcumin therapeutic mechanisms and clinical evidence in MASLD, with a focus on its antioxidant effect, improvement of mitochondrial function, anti-inflammatory effect, reduction of insulin resistance, and regulation of gut microbiota. It also examines the current efficacy and limitations of curcumin-based combination therapies and their derivatives in the treatment of MASLD. As research on MASLD progresses, curcumin shows great potential for therapeutic applications. Future studies should target long-term impacts, such as subclinical oxidative stress and epigenetic modifications. Furthermore, this article addresses persistent challenges such as curcumin's inherently low bioavailability and the lack of standardized dosing protocols, which should guide future clinical research efforts.